Challenges in neuronal apoptosis

Current Alzheimer Research

Volumn 3, Issue 4, 2006, Pages 377-391

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

amyloid protein; Alzheimer disease; Apoptosis; Caspases; Cell cycle; Death effector domain; Programmed cell death; Signaling pathways; Tau phosphorylation

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; CASPASE 3; CASPASE INHIBITOR; DNA FRAGMENT; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; INCIDENCE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; AUTOPHAGY; BRAIN; CASPASES; DNA FRAGMENTATION; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 33748474961     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506778249434     Document Type: Review

References (202)

1. Ashe PC and Berry MD. Apoptotic signaling cascades. Prog Neuropsychopharmacol Biol Psychiatry 27: 199-214 (2003).
2. Becker EB and Bonni A. Cell cycle regulation of neuronal apoptosis in development and disease. Prog Neurobiol 72: 1-25 (2004).
3. Kerr JF, Wyllie AH and Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257 (1972).
4. Kuhtreiber WM, Hayashi T, Dale EA and Faustman DL. Central role of defective apoptosis in autoimmunity. J Mol Endocrinol 31: 373-399 (2003).
5. Lorenz HM, Herrmann M, Winkler T, Gaipl U and Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 5: 443-449 (2000).
6. Flemming W. Ueber die Bildung von Richtungsfiguren in Saeugethiereiern beim Untergang Graaf'scher Follikel. Arch Anat Physiol: 221-224 (1885).
7. Clarke PGH. Apoptosis versus necrosis. In 'Cell death and disease of the nervous system' (Eds Koliatsosue M, Ratan RR). Humana Press, Totowa, NY, pp. 3-28 (1999).
8. Levin S, Bucci TJ, Cohen SM, Fix AS, Hardisty JF, LeGrand EK, et al. The nomenclature of cell death: recommendations of an ad hoc Committee of the Society of Toxicologic Pathologists. Toxicol Pathol 27: 484-490 (1999).
9. Wyllie AH, Kerr JF and Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306 (1980).
10. Almeida CJ and Linden R. Phagocytosis of apoptotic cells: a matter of balance. Cell Mol Life Sci: (2005).
11. Klionsky DJ and Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 290: 1717-1721 (2000).
12. Nixon RA, Yu WH, Cuervo AM, Kumar A, Yang DS and Peterhoff C. Autophagy in Alzheimer's disease: failure of a neuroprotective mechanism. In 'Recent Advances in Alzheimer's Disease and Related Disorders 2004' (Eds Iqbal K, Winblad B). Alzheimer's Association, Chicago, IL, pp. 190-201 (2005).
13. Gorman AM, Ceccatelli S and Orrenius S. Role of mitochondria in neuronal apoptosis. Dev Neurosci 22: 348-358 (2000).
14. Nicotera P, Leist M and Ferrando-May E. Apoptosis and necrosis: different execution of the same death. Biochem Soc Symp 66: 69-73 (1999).
15. Desagher S and Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol 10: 369-377 (2000).
16. Jellinger KA and Stadelmann C. Problems of cell death in neurodegeneration and Alzheimer's Disease. J Alzheimers Dis 3: 31-40 (2001).
17. Portera-Cailliau C, Price DL and Martin LJ. Excitotoxic neuronal death in the immature brain is an apoptosis-necrosis morphological continuum. J Comp Neurol 378: 70-87 (1997).
18. Martin LJ. Neuronal cell death in nervous system development, disease, and injury (Review). Int J Mol Med 7: 455-478 (2001).
19. Jellinger KA and Stadelmann CH. The enigma of cell death in neurodegenerative disorders. J Neural Transm Suppl: 21-36 (2000).
20. Graeber MB and Moran LB. Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts. Brain Pathol 12: 385-390 (2002).
21. Lockshin RA and Zakeri Z. Apoptosis, autophagy, and more. Int J Biochem Cell Biol 36: 2405-2419 (2004).
22. Nicotera P and Melino G. Regulation of the apoptosis-necrosis switch. Oncogene 2757-65: 2757-2765 (2004).
23. Yuan J, Lipinski M and Degterev A. Diversity in the mechanisms of neuronal cell death. Neuron 40: 401-413 (2003).
24. Harwood SM, Yaqoob MM and Allen DA. Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis. Ann Clin Biochem 42: 415-431 (2005).
25. Jellinger KA. Apoptosis vs nonapoptotic mechanisms in neurodegeneration. In 'Neuroinflammation. 2nd Edition' (Ed Wood PL). Human Press, Totowa, NJ, pp 29-88 (2003).
26. Bredesen DE. Apoptosis: overview and signal transduction pathways. J Neurotrauma 17: 801-810 (2000).
27. Wyllie AH. Apoptosis: an overview. Br Med Bull 53: 451-465 (1997).
28. Yuan J and Yankner BA. Apoptosis in the nervous system. Nature 407: 802-809 (2000).
29. Ayala-Grosso C, Ng G, Roy S and Robertson GS. Csp-cleaved amyloid precursor protein in Alzheimer's disease. Brain Pathol 12: 430-441 (2002).
30. Faherty CJ and Smeyne RJ. Cell death in Parkinson's disease. In 'Parkinson's Disease' (Eds Ebadi M, Pfeiffer RF). CRC Press, Boca Raton, London, New York, Washington, pp 523-535 (2005).
31. Kermer P, Liman J, Weishaupt JH and Baehr M. Neuronal apoptosis in neurodegenerative diseases: from basic research to clinical application. Neurodeg Dis 1: 9-19 (2004).
32. Newman J, Rissman RA, Sarsoza F, Kim RC, Dick M, Bennett DA, et al. Csp-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol (Berl) 110: 135-144 (2005).
33. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, et al. Csp-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114: 121-130 (2004).
34. Roth KA. Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. J Neuropathol Exp Neurol 60: 829-838 (2001).
35. Sathasivam S, Ince PG and Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 27: 257-274 (2001).
36. Schulz JB and Falkenburger BH. Neuronal pathology in Parkinson's disease. Cell Tissue Res 318: 135-147 (2004).
37. Tatton WG and Olanow CW. Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta 1410: 195-213 (1999).
38. Vis JC, Schipper E, de Boer-van Huizen RT, Verbeek MM, de Waal RM, Wesseling P, et al. Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol (Berl) 109: 321-328 (2005).
39. Cotman CW. Apoptosis decision cascades and neuronal degeneration in Alzheimer's disease. Neurobiol Aging 19: S29-32 (1998).
40. Cotman CW, Poon WW, Rissman RA and Blurton-Jones M. The role of Csp cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol 64: 104-112 (2005).
41. Cotman CW, Qian HY and Anderson AJ. Cellular signaling pathways in neuronal apoptosis. Role in neurodegeneration and Alzheimer's disease. In 'Cerebral Signal Transduction. From First to Fourth Messengers' (Ed Reith MEA). Humana Press, Totowa, NJ, pp. 175-206 (2000).
42. Jellinger KA. General aspects of neurodegeneration. J Neural Transm Suppl: 101-144 (2003).
43. Hirsch EC, Hunot S, Faucheux B, Agid Y, Mizuno Y, Mochizuki H, et al. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord 14: 383-385 (1999).
44. Mattson MP. Mechanisms of neuronal apoptosis and excitotoxicity. In 'Pathogenesis of Neurodegenerative Disorders' (Ed Mattson MP). Humana Press, Totowa, NJ, pp. 1-20 (2001).
45. Raina AK, Hochman A, Zhu X, Rottkamp CA, Nunomura A, Siedlak SL, et al. Abortive apoptosis in Alzheimer's disease. Acta Neuropathol (Berl) 101: 305-310 (2001).
46. Reed JC. Mechanisms of apoptosis. Am J Pathol 157: 1415-1430 (2000).
47. Prunell GF and Troy CM. Balancing neuronal death. J Neurosci Res 78: 1-6 (2004).
48. Agerman K, Baudet C, Fundin B, Willson C and Ernfors P. Attenuation of a Csp-3 dependent cell death in NT4- and p75-deficient embryonic sensory neurons. Mol Cell Neurosci 16: 258-268 (2000).
49. Ashkenazi A and Dixit VM. Death receptors: signaling and modulation. Science 281: 1305-1308 (1998).
50. LeBlanc AC, ed Apoptosis Techniques and Protocols, 2nd Edition. Totowa, NJ, Humana Press (2002).
51. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 1: 111-121 (2002).
52. Bratton SB and Cohen GM. Apoptotic death sensor: an organelle's alter ego? Trends Pharmacol Sci 22: 306-315 (2001).
53. Gerhardt E, Kugler S, Leist M, Beier C, Berliocchi L, Volbracht C, et al. Cascade of Csp activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis. Mol Cell Neurosci 17: 717-731 (2001).
54. Guo H, Petrin D, Zhang Y, Bergeron C, Goodyer CG and LeBlanc AC. Caspase-1 activation of caspase-6 in human apoptotic neurons. Cell Death Differ 13: 285-292 (2006).
55. Velier JJ, Ellison JA, Kikly KK, Spera PA, Barone FC and Feuerstein GZ. Csp-8 and Csp-3 are expressed by different populations of cortical neurons undergoing delayed cell death after focal stroke in the rat. J Neurosci 19: 5932-5941 (1999).
56. Budd SL, Tenneti L, Lishnak T and Lipton SA. Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proc Natl Acad Sci U S A 97: 6161-6166 (2000).
57. Hetz CA, Torres V and Quest AF. Beyond apoptosis: nonapoptotic cell death in physiology and disease. Biochem Cell Biol 83: 579-588 (2005).
58. Kroemer G and Martin SJ. Csp-independent cell death. Nat Med 11: 725-730 (2005).
59. Armstrong JS. Mitochondrial membrane permeabilization: the sine qua non for cell death. Bioessays 28: 253-260 (2006).
60. Krieger C and Duchen MR. Mitochondria, Ca2+ and neurodegenerative disease. Eur J Pharmacol 447: 177-188 (2002).
61. Jordan J, Cena V and Prehn JH. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J Physiol Biochem 59: 129-141 (2003).
62. Gross A, McDonnell JM and Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911 (1999).
63. Kroemer G and Reed JC. Mitochondrial control of cell death. Nat Med 6: 513-519 (2000).
64. Zou H, Li Y, Liu X and Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274: 11549-11556 (1999).
65. Qin H, Srinivasula SM, Wu G, Fernandes-Alnemri T, Alnemri ES and Shi Y. Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1. Nature 399: 549-557 (1999).
66. Salvesen GS and Dixit VM. Csp activation: the induced-proximity model. Proc Natl Acad Sci U S A 96: 10964-10967 (1999).
67. Hengartner MO. The biochemistry of apoptosis. Nature 407: 770-776 (2000).
68. Stefanis L. Csp-dependent and -independent neuronal death: two distinct pathways to neuronal injury. Neuroscientist 11: 50-62 (2005).
69. [64a] Kim R, Emi M, Tanabe K, Murakami S, Uchida Y and Arihiro K. Regulation and interplay of apoptotic and non-apoptotic cell death. J Pathol 208: 319-326 (2006).
70. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410: 549-554 (2001).
71. Longuet M, Serduc R and Riva C. Implication of bax in apoptosis depends on microtubule network mobility. Int J Oncol 25: 309-317 (2004).
72. Roth KA, Kuan C, Haydar TF, D'Sa-Eipper C, Shindler KS, Zheng TS, et al. Epistatic and independent functions of Csp-3 and Bcl-X(L) in developmental programmed cell death. Proc Natl Acad Sci U S A 97: 466-471 (2000).
73. Cregan SP, MacLaurin JG, Craig CG, Robertson GS, Nicholson DW, Park DS, et al. Bax-dependent Csp-3 activation is a key determinant in p53-induced apoptosis in neurons. J Neurosci 19: 7860-7869 (1999).
74. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG and Green DR. Bax-induced Csp activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 274: 2225-2233 (1999).
75. Takayama S and Reed JC. Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol 3: E237-241 (2001).
76. Kermer P, Digicaylioglu MH, Kaul M, Zapata JM, Krajewska M, Stenner-Liewen F, et al. BAG1 over-expression in brain protects against stroke. Brain Pathol 13: 495-506 (2003).
77. Roth W, Kermer P, Krajewska M, Welsh K, Davis S, Krajewski S, et al. Bifunctional apoptosis inhibitor (BAR) protects neurons from diverse cell death pathways. Cell Death Differ 10: 1178-1187 (2003).
78. Boonman Z and Isacson O. Apoptosis in neuronal development and transplantation: role of caspases and trophic factors. Exp Neurol 156: 1-15 (1999).
79. [73a] Butts BD, Hudson HR, Linseman DA, Le SS, Ryan KR, Bouchard RJ, et al. Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and proapoptotic transcription factors. Mol Cell Neurosci 30: 279-289 (2005).
80. Mattson MP, Duan W, Chan SL and Camandola S. Par-4: an emerging pivotal player in neuronal apoptosis and neurodegenerative disorders. J Mol Neurosci 13: 17-30 (1999).
81. Culmsee C and Mattson MP. p53 in neuronal apoptosis. Biochem Biophys Res Commun 331: 761-777 (2005).
82. Martin LJ, Chen K and Liu Z. Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. J Neurosci 25: 6449-6459 (2005).
83. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, et al. p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun 331: 713-717 (2005).
84. Lin L, Ye Y and Zakeri Z. p53, Apaf-1, Csp-3, and -9 are dispensable for Cdk5 activation during cell death. Cell Death Differ: 13: 141-150 (2005).
85. [78a] Krantic S, Mechawar N, Reix S and Quirion R. Molecular basis of programmed cell death involved in neurodegeneration. Trends Neurosci 28: 670-676 (2005).
86. Davydov V, Hansen LA and Shackelford DA. Is DNA repair compromised in Alzheimer's disease? Neurobiol Aging 24: 953-968 (2003).
87. Culmsee C, Bondada S and Mattson MP. Hippocampal neurons of mice deficient in DNA-dependent protein kinase exhibit increased vulnerability to DNA damage, oxidative stress and excitotoxicity. Brain Res Mol Brain Res 87: 257-262 (2001).
88. Gilmore EC, Nowakowski RS, Caviness VS, Jr. and Herrup K. Cell birth, cell death, cell diversity and DNA breaks: how do they all fit together? Trends Neurosci 23: 100-105 (2000).
89. Du C, Fang M, Li Y, Li L and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent Csp activation by eliminating IAP inhibition. Cell 102: 33-42 (2000).
90. Jaattela M, Wissing D, Kokholm K, Kallunki T and Egeblad M. Hsp70 exerts its anti-apoptotic function downstream of Csp-3-like proteases. Embo J 17: 6124-6134 (1998).
91. Volbracht C, Leist M, Kolb SA and Nicotera P. Apoptosis in Csp-inhibited neurons. Mol Med 7: 36-48 (2001).
92. Ha HC and Snyder SH. Poly(ADP-ribose) polymerase-1 in the nervous system. Neurobiol Dis 7: 225-239 (2000).
93. Sheline CT, Wang H, Cai AL, Dawson VL and Choi DW. Involvement of poly ADP ribosyl polymerase-1 in acute but not chronic zinc toxicity. Eur J Neurosci 18: 1402-1409 (2003).
94. Herdegen T, Skene P and Bahr M. The c-Jun transcription factor - bipotential mediator of neuronal death, survival and regeneration. Trends Neurosci 20: 227-231 (1997).
95. Pozas E, Ballabriga J, Planas AM and Ferrer I. Kainic acid-induced excitotoxicity is associated with a complex c-Fos and c-Jun response which does not preclude either cell death or survival. J Neurobiol 33: 232-246 (1997).
96. Bozyczko-Coyne D, Saporito MS and Hudkins RL. Targeting the JNK pathway for therapeutic benefit in CNS disease. Curr Drug Targets CNS Neurol Disord 1: 31-49 (2002).
97. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1: 120-129 (2000).
98. [90a] Langley B and Ratan RR. Oxidative stress-induced death in the nervous system: cell cycle dependent or independent? J Neurosci Res 77: 621-629 (2004).
99. [90b] Kruman, II, Wersto RP, Cardozo-Pelaez F, Smilenov L, Chan SL, Chrest FJ, et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 41: 549-561 (2004).
100. Wolozin B and Behl C. Mechanisms of neurodegenerative disorders: Part 1: protein aggregates. Arch Neurol 57: 793-796 (2000).
101. Jellinger KA. Cell death mechanisms in neurodegeneration. J Cell Mol Med 5: 1-17 (2001).
102. Duda JE, Lee VM and Trojanowski JQ. Neuropathology of synuclein aggregates. J Neurosci Res 61: 121-127 (2000).
103. Kahns S, Lykkebo S, Jakobsen LD, Nielsen MS and Jensen PH. Csp-mediated parkin cleavage in apoptotic cell death. J Biol Chem 277: 15303-15308 (2002).
104. Lee SS, Kim YM, Junn E, Lee G, Park KH, Tanaka M, et al. Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. Neurobiol Aging 24: 687-696 (2003).
105. Lucking CB and Brice A. Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci 57: 1894-1908 (2000).
106. [96a] Kim R, Emi M, Tanabe K and Murakami S. Role of the unfolded protein response in cell death. Apoptosis 11: 5-13 (2006).
107. [96b] Fadeel B and Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 258: 479-517 (2005).
108. Sathasivam S and Shaw PJ. Apoptosis in amyotrophic lateral sclerosis - what is the evidence? Lancet Neurol 4: 500-509 (2005).
109. Knopman DS. Alzheimer type dementia. In 'Neurodegeneration. The Molecular Pathology of Dementia and Movement Disorders' (Ed Dickson DW). ISN Neuropath Press, Basel, pp. 24-39 (2003).
110. Mirra SS and Hyman BT. Aging and dementia. In 'Greenfield's Neuropathology, 7th Ed.' (Eds Graham DI, Lantos PL). E. Arnold, London, pp. 195-271 (2002).
111. Braak H and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259. (1991).
112. McKeel DW, Price JL, Miller JP, Grant EA, Xiong C, Berg L, et al. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. J Neuropathol Exp Neurol 63: 1028-1037 (2004).
113. Duyckaerts C and Dickson DW. Neuropathology of Alzheimer's disease. In 'Neurodegeneration. The Molecular Pathology of Dementia and Movement Disorders' (Ed Dickson DW). ISN Neuropath Press Basel, pp. 47-65 (2003).
114. Morris JH and Nagy Z. Alzheimer's disease. In 'The Neuropathology of Dementia' (Eds Esiri M, Lee VMY, Trojanowski JQ). Cambridge University Press, Cambridge, pp. 161-206 (2004).
115. Masters CL and Beyreuther K. Molecular Pathogenesis of Alzheimer's disease. In 'Neurodegeneration. The Molecular Pathology of Dementia and Movement Disorders' (Ed Dickson DW). ISN Neuropath Press Basel, pp. 69-73 (2003).
116. Buée L, Bussiere T, Buee-Scherrer V, Delacourte A and Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33: 95-130 (2000).
117. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59: 398-407. (2002).
118. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
119. LeVine H, 3rd. The Amyloid Hypothesis and the clearance and degradation of Alzheimer's beta-peptide. J Alzheimers Dis 6: 303-314 (2004).
120. Ferrari A, Hoerndli F, Baechi T, Nitsch RM and Gotz J. beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem 278: 40162-40168 (2003).
121. Selznick LA, Zheng TS, Flavell RA, Rakic P and Roth KA. Amyloid beta-induced neuronal death is bax-dependent but Csp-independent. J Neuropathol Exp Neurol 59: 271-279 (2000).
122. Allen JW, Eldadah BA, Huang X, Knoblach SM and Faden AI. Multiple caspases are involved in beta-amyloid-induced neuronal apoptosis. J Neurosci Res 65: 45-53 (2001).
123. Pereira C, Ferreiro E, Cardoso SM and de Oliveira CR. Cell degeneration induced by amyloid-beta peptides: implications for Alzheimer's disease. J Mol Neurosci 23: 97-104 (2004).
124. Cardoso SM and Oliveira CR. The role of calcineurin in amyloid-beta-peptides-mediated cell death. Brain Res 1050: 1-7 (2005).
125. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97: 395-406 (1999).
126. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW and Head E. Csp-9 activation and Csp cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 11: 341-354 (2002).
127. Rohn TT, Rissman RA, Head E and Cotman CW. Csp Activation in the Alzheimer's Disease Brain: Tortuous and Torturous. Drug News Perspect 15: 549-557 (2002).
128. Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP and Inestrosa NC. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res Brain Res Rev 47: 275-289 (2004).
129. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Csp cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100: 10032-10037 (2003).
130. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C and Le-Blanc AC. Active Csp-6 and Csp-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 165: 523-531 (2004).
131. Oddo S, Billings L, Kesslak JP, Cribbs DH and LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321-332 (2004).
132. Chung CW, Song YH, Kim IK, Yoon WJ, Ryu BR, Jo DG, et al. Proapoptotic effects of tau cleavage product generated by Csp-3. Neurobiol Dis 8: 162-172 (2001).
133. Gotz J, Chen F, van Dorpe J and Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-1495 (2001).
134. Oddo S, Caccamo A, Kitazawa M, Tseng BP and LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24: 1063-1070 (2003).
135. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribé E, Dalfó E, et al. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2: 3-18 (2005).
136. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, et al. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 88: 554-563 (2004).
137. Kins S, Kurosinski P, Nitsch RM and Gotz J. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 163: 833-843 (2003).
138. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W and Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22: RC221 (2002).
139. Ferrer I, Blanco R, Carmona M and Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 108: 1397-1415 (2001).
140. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 11: 144-158 (2001).
141. Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, et al. The neuronal microtubule-associated protein tau is a substrate for Csp-3 and an effector of apoptosis. J Neurochem 75: 624-633 (2000).
142. Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, et al. Early N-terminal changes and Csp-6 cleavage of tau in Alzheimer's disease. J Neurosci 24: 7895-7902 (2004).
143. Kobayashi K, Nakano H, Hayashi M, Shimazaki M, Fukutani Y, Sasaki K, et al. Association of phosphorylation site of tau protein with neuronal apoptosis in Alzheimer's disease. J Neurol Sci 208: 17-24 (2003).
144. Kang HJ, Yoon WJ, Moon GJ, Kim DY, Sohn S, Kwon HJ, et al. Csp-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease. Neurobiol Dis 18: 450-458 (2005).
145. Masliah E, Mallory M, Alford M, Tanaka S and Hansen LA. Csp dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J Neuropathol Exp Neurol 57: 1041-1052 (1998).
146. Gastard MC, Troncoso JC and Koliatsos VE. Csp activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 54: 393-398 (2003).
147. Pompl PN, Yemul S, Xiang Z, Ho L, Haroutunian V, Purohit D, et al. Csp gene expression in the brain as a function of the clinical progression of Alzheimer disease. Arch Neurol 60: 369-376 (2003).
148. Cribbs DH, Poon WW, Rissman RA and Blurton-Jones M. Csp-mediated degeneration in Alzheimer's disease. Am J Pathol 165: 353-355 (2004).
149. Rametti A, Esclaire F, Yardin C and Terro F. Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J Biol Chem 279: 54518-54528 (2004).
150. Dickson DW. Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest 114: 23-27 (2004).
151. Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A and Cohen GM. Csp activation inhibits proteasome function during apoptosis. Mol Cell 14: 81-93 (2004).
152. Braak H and Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18: 351-357 (1997).
153. Duyckaerts C and Hauw JJ. Prevalence, incidence and duration of Braak's stages in the general population: can we know? Neurobiol Aging 18: 362-369; discussion 389-392 (1997).
154. Guzik BW and Goldstein LS. Microtubule-dependent transport in neurons: steps towards an understanding of regulation, function and dysfunction. Curr Opin Cell Biol 16: 443-450 (2004).
155. Mandelkow EM, Stamer K, Vogel R, Thies E and Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24: 1079-1085 (2003).
156. Roy S, Zhang B, Lee VM and Trojanowski JQ. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol (Berl) 109: 5-13 (2005).
157. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-1288 (2005).
158. [146a] Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, Bresciani LG, et al. NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci 23: 1711-1720 (2006).
159. Dimakopoulos AC. Protein aggregation in Alzheimer's disease and other neuropathological disorders. Curr Alzheimer Res 2: 19-28 (2005).
160. Gsell W, Jungkunz G and Riederer P. Functional neurochemistry of Alzheimer's disease. Curr Pharm Design 9: 265-293 (2003).
161. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res 1: 39-46 (2004).
162. Thal DR, Rub U, Orantes M and Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800 (2002).
163. Rademakers R, Sleegers K, Theuns J, Van den Broeck M, Bel Kacem S, Nilsson LG, et al. Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease. Neurobiol Aging 26: 1145-1151 (2005).
164. Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, et al. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 306: 116-120 (2001).
165. Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, et al. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem 77: 849-863 (2001).
166. Fogarty MP, Downer EJ and Campbell V. A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons. Biochem J 371: 789-798 (2003).
167. Jang JH and Surh YJ. beta-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann N Y Acad Sci 973: 228-236 (2002).
168. Tamagno E, Robino G, Obbili A, Bardini P, Aragno M, Parola M, et al. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 180: 144-155 (2003).
169. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, et al. beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem 77: 157-164 (2001).
170. Wei W, Norton DD, Wang X and Kusiak JW. Abeta 17-42 in Alzheimer's disease activates JNK and Csp-8 leading to neuronal apoptosis. Brain 125: 2036-2043 (2002).
171. Daniels WM, Hendricks J, Salie R and Taljaard JJ. The role of the MAP-kinase superfamily in beta-amyloid toxicity. Metab Brain Dis 16: 175-185 (2001).
172. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 21: 7551-7560 (2001).
173. Selznick LA, Holtzman DM, Han BH, Gokden M, Srinivasan AN, Johnson EM, Jr., et al. In situ immunodetection of neuronal Csp-3 activation in Alzheimer disease. J Neuropathol Exp Neurol 58: 1020-1026 (1999).
174. Zhu X, Raina AK, Lee HG, Chao M, Nunomura A, Tabaton M, et al. Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid Redox Signal 5: 571-576 (2003).
175. Hamdane M, Delobel P, Sambo AV, Smet C, Begard S, Violleau A, et al. Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis? Biochem Pharmacol 66: 1619-1625 (2003).
176. Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol (Berl) 89: 35-41 (1995).
177. Lucassen PJ, Chung WC, Kamphorst W and Swaab DF. DNA damage distribution in the human brain as shown by in situ end labeling; area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology. J Neuropathol Exp Neurol 56: 887-900 (1997).
178. Sugaya K, Reeves M and McKinney M. Topographic associations between DNA fragmentation and Alzheimer's disease neuropathology in the hippocampus. Neurochem Int 31: 275-281 (1997).
179. Troncoso JC, Sukhov RR, Kawas CH and Koliatsos VE. In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: correlations with senile plaques and disease progression. J Neuropathol Exp Neurol 55: 1134-1142 (1996).
180. Woodhouse A, Dickson TC, West AK, McLean CA and Vickers JC. No difference in expression of apoptosis-related proteins and apoptotic morphology in controls, pathologically aged and Alzheimer's disease cases. Neurobiol Dis 22: 323-333 (2005).
181. Su JH, Kesslak JP, Head E and Cotman CW. Csp-cleaved amyloid precursor protein and activated Csp-3 are co-localized in the granules of granulovacuolar degeneration in Alzheimer's disease and Down's syndrome brain. Acta Neuropathol (Berl) 104: 1-6 (2002).
182. Ghoshal N, Smiley JF, DeMaggio AJ, Hoekstra MF, Cochran EJ, Binder LI, et al. A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. Am J Pathol 155: 1163-1172 (1999).
183. Anderson AJ, Su JH and Cotman CW. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 16: 1710-1719 (1996).
184. Giannakopoulos P, Kovari E, Savioz A, de Bilbao F, Dubois-Dauphin M, Hof PR, et al. Differential distribution of presenilin-1, Bax, and Bcl-X(L) in Alzheimer's disease and frontotemporal dementia. Acta Neuropathol (Berl) 98: 141-149 (1999).
185. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res 780: 260-269 (1998).
186. Engidawork E, Gulesserian T, Yoo BC, Cairns N and Lubec G. Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 281: 84-93 (2001).
187. Nagy ZS and Esiri MM. Apoptosis-related protein expression in the
188. Yang Y, Geldmacher DS and Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21: 2661-2668 (2001).
189. Yang AJ, Chandswangbhuvana D, Margol L and Glabe CG. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 52: 691-698 (1998).
190. Stadelmann C, Bruck W, Bancher C, Jellinger K and Lassmann H. Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol 57: 456-464 (1998).
191. Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Bruck W, Jellinger K, et al. Activation of Csp-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol 155: 1459-1466 (1999).
192. Del Villar K and Miller CA. Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons. Proc Natl Acad Sci U S A 101: 4210-4215 (2004).
193. Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19: 597-598 (2005).
194. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y and Jacobson MD. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 262: 695-700 (1993).
195. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J 19: 255-257 (2005).
196. de la Monte SM, Luong T, Neely TR, Robinson D and Wands JR. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest 80: 1323-1335 (2000).
197. Perry G, Nunomura A, Lucassen P, Lassmann H and Smith MA. Apoptosis and Alzheimer's disease. Science 282: 1268-1269 (1998).
198. Morsch R, Simon W and Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58: 188-197 (1999).
199. Sampson VL, Morrison JH and Vickers JC. The cellular basis for the relative resistance of parvalbumin and calretinin immunoreactive neocortical neurons to the pathology of Alzheimer's disease. Exp Neurol 145: 295-302 (1997).
200. Vickers JC, Tan A and Dickson TC. Direct determination of the proportion of intra- and extra-cellular neocortical neurofibrillary tangles in Alzheimer's disease. Brain Res 971: 135-137 (2003).
201. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K and Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25: 5446-5454 (2005).
202. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481 (2005).